<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="FABP4 in ovarian cancer" Version="20181023" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Regulation of FABP4 in ovarian cancer. FABP4 (fatty acid binding protein) can substantially increase metastatic potential of ovarian cancer cells, and leads to more aggressive disease. Mir-409-3p negatively regulates FABP4 in ovarian cancer cells, and mir-409-3p is decreased in hypoxic conditions. Pink arrows indicates potential therapuetic therapeutic stratgeies; in Gharpure et al, DOPC nanoliposomes containing either miR-409-3p mimic or FABP4 siRNA was shown to inhibit tumor progression. 
Description was adapted from Gharpure et al. </Comment>
  <BiopaxRef>cf7</BiopaxRef>
  <Graphics BoardWidth="907.0" BoardHeight="551.5"/>
  <DataNode TextLabel="FABP4" GraphId="cce25" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="MIR409" GraphId="d26ef" Type="Rna">
    <Graphics Color="990099"/>
    </DataNode>
  <Interaction>
    <Graphics>
      <Point GraphRef="d26ef"/>
      <Point GraphRef="cce25" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction>
    <Graphics>
      <Point GraphRef="ecf0a"/>
      <Point GraphRef="d26ef" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction>
    <Graphics Color="ff0066">
      <Point GraphRef="d9a66"/>
      <Point GraphRef="cce25" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction>
    <Graphics LineStyle="Broken">
      <Point GraphRef="cce25"/>
      <Point GraphRef="ddb85" ArrowHead="mim-conversion"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="aec65">
    <Graphics Color="ff0066">
      <Point GraphRef="be356"/>
      <Point GraphRef="cce25" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <GraphicalLine GraphId="aa89a" GroupRef="c0227">
    <Graphics Color="ff0066">
      <Point/>
      <Point/>
    </Graphics>
  </GraphicalLine>
  <Label TextLabel="Potential therapeutic strategies" GraphId="aa4b7" GroupRef="c0227">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Aggressive disease" GraphId="ddb85">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="mir-409-3p &#10;mimic" GraphId="eab5f" GroupRef="cfc14">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Hypoxia" GraphId="ecf0a">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="FABP4&#10;siRNA" GraphId="bb40a" GroupRef="b76a3">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Shape TextLabel="Legend" GraphId="a95a4" GroupRef="c0227">
    <Graphics Align="Left" ShapeType="Rectangle"/>
  </Shape>
  <Shape TextLabel="Tumor cell" GraphId="af894">
    <Graphics ShapeType="Oval" Color="c0c0c0"/>
  </Shape>
  <Shape GraphId="ce409" GroupRef="cfc14">
    <Graphics ShapeType="Oval" Color="c0c0c0"/>
  </Shape>
  <Shape GraphId="c62ae" GroupRef="b76a3">
    <Graphics ShapeType="Oval" Color="c0c0c0"/>
  </Shape>
  <Group GroupId="c0227" Style="Group"/>
  <Group GroupId="b76a3" GraphId="be356" Style="Group"/>
  <Group GroupId="cfc14" GraphId="d9a66" Style="Group"/>
  <Group GroupId="d567c" GraphId="d7327" Style="Group"/>
  <InfoBox/>
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cf7">
      <bp:ID >30050129</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >FABP4 as a key determinant of metastatic potential of ovarian cancer.</bp:TITLE>
      <bp:SOURCE >Nat Commun</bp:SOURCE>
      <bp:YEAR >2018</bp:YEAR>
      <bp:AUTHORS >Gharpure KM</bp:AUTHORS>
      <bp:AUTHORS >Pradeep S</bp:AUTHORS>
      <bp:AUTHORS >Sans M</bp:AUTHORS>
      <bp:AUTHORS >Rupaimoole R</bp:AUTHORS>
      <bp:AUTHORS >Ivan C</bp:AUTHORS>
      <bp:AUTHORS >Wu SY</bp:AUTHORS>
      <bp:AUTHORS >Bayraktar E</bp:AUTHORS>
      <bp:AUTHORS >Nagaraja AS</bp:AUTHORS>
      <bp:AUTHORS >Mangala LS</bp:AUTHORS>
      <bp:AUTHORS >Zhang X</bp:AUTHORS>
      <bp:AUTHORS >Haemmerle M</bp:AUTHORS>
      <bp:AUTHORS >Hu W</bp:AUTHORS>
      <bp:AUTHORS >Rodriguez-Aguayo C</bp:AUTHORS>
      <bp:AUTHORS >McGuire M</bp:AUTHORS>
      <bp:AUTHORS >Mak CSL</bp:AUTHORS>
      <bp:AUTHORS >Chen X</bp:AUTHORS>
      <bp:AUTHORS >Tran MA</bp:AUTHORS>
      <bp:AUTHORS >Villar-Prados A</bp:AUTHORS>
      <bp:AUTHORS >Pena GA</bp:AUTHORS>
      <bp:AUTHORS >Kondetimmanahalli R</bp:AUTHORS>
      <bp:AUTHORS >Nini R</bp:AUTHORS>
      <bp:AUTHORS >Koppula P</bp:AUTHORS>
      <bp:AUTHORS >Ram P</bp:AUTHORS>
      <bp:AUTHORS >Liu J</bp:AUTHORS>
      <bp:AUTHORS >Lopez-Berestein G</bp:AUTHORS>
      <bp:AUTHORS >Baggerly K</bp:AUTHORS>
      <bp:AUTHORS >S Eberlin L</bp:AUTHORS>
      <bp:AUTHORS >Sood AK</bp:AUTHORS>
    </bp:PublicationXref>
  <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"><bp:TERM>ovarian cancer</bp:TERM><bp:ID>DOID:2394</bp:ID><bp:Ontology>Disease</bp:Ontology></bp:openControlledVocabulary><bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"><bp:TERM>microRNA pathway</bp:TERM><bp:ID>PW:0000808</bp:ID><bp:Ontology>Pathway Ontology</bp:Ontology></bp:openControlledVocabulary><bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"><bp:TERM>cancer pathway</bp:TERM><bp:ID>PW:0000605</bp:ID><bp:Ontology>Pathway Ontology</bp:Ontology></bp:openControlledVocabulary></Biopax>
</Pathway>